Revolution Medicines Highlights P-III (RASolute 302) Trial Results on Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer

Why It Matters

The results could establish the first KRAS‑directed therapy to improve survival in pancreatic cancer, a disease with few effective options, and may reshape treatment standards for both KRAS‑mutated and broader patient populations.

Key Takeaways

• Daraxonrasib cut median overall survival to 13.2 months vs 6.6 months.
• Progression‑free survival doubled to ~7.3 months versus standard chemotherapy.
• Objective response rate rose above 30%, triple that of control.
• Benefits observed regardless of KRAS G12 mutation status.
• FDA granted expanded‑access program ahead of formal NDA filing.

Pulse Analysis

Metastatic pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid tumors, with a five‑year survival rate below 10 percent and limited therapeutic options after first‑line chemotherapy. Approximately 90 % of PDAC tumors harbor KRAS mutations, yet direct inhibition of this oncogene has long been considered undruggable. Recent advances in covalent KRAS‑G12 inhibitors have opened a new frontier, offering the possibility of targeting the molecular driver that fuels tumor growth and resistance. Daraxonrasib, Revolution Medicines’ oral KRAS‑G12C/D inhibitor, entered the spotlight as the first agent to demonstrate a survival advantage in this setting.

The Phase III RASolute 302 trial enrolled 500 patients who had progressed on prior lines of therapy, randomizing them to daraxonrasib 300 mg daily or physician’s choice chemotherapy. Daraxonrasib extended median overall survival to 13.2 months—a 60 % improvement over the 6.6‑6.7 month control—while median progression‑free survival more than doubled to 7.3 months. Objective response rates climbed to 33 % versus roughly 12 % with chemotherapy, and patients reported slower deterioration in pain and quality‑of‑life metrics. Importantly, these benefits were observed both in the KRAS G12‑mutant subgroup and in the intent‑to‑treat population, suggesting a broader therapeutic window.

Regulatory momentum is already building. The FDA has granted an expanded‑access program for eligible patients while Revolution prepares an NDA under a collaborative‑registration pathway (CNPV). If approved, daraxonrasib would become the first KRAS‑directed therapy to demonstrate overall‑survival benefit in pancreatic cancer, potentially displacing standard cytotoxic regimens and opening combination opportunities with immunotherapy or targeted agents. The market, estimated at $2 billion annually for later‑line PDAC treatments, could see a rapid shift toward precision‑medicine approaches, bolstering Revolution’s pipeline credibility and attracting partnership interest.